Long-term protective potency of AAV vector-based SARS-CoV-2 prophylaxis in mice and non-human primates - Takeaways - MDSpire

Long-term protective potency of AAV vector-based SARS-CoV-2 prophylaxis in mice and non-human primates

  • By

  • Ekaterina I. Ryabova

  • Artem A. Derkaev

  • Ilias B. Esmagambetov

  • Mikhail A. Dovgiy

  • Ilya V. Gordeychuk

  • Inna V. Shuliakova

  • Rosa M. Hossain

  • Anton A. Blinov

  • Anna A. Iliukhina

  • Daria M. Grousova

  • Ilya D. Zorkov

  • Daria V. Avdoshina

  • Stanislav A. Gulyaev

  • Vasiliy D. Apolokhov

  • Tatiana V. Gulyaeva

  • Irina A. Favorskaya

  • Dmitry V. Shcheblyakov

  • Alexander L. Gintsburg

  • Denis Y. Logunov

  • June 4, 2026

  • 0 min

Share

  • 1

    Recombinant adeno-associated virus (rAAV) delivery of neutralizing antibodies offers a strategy for long-term SARS-CoV-2 prophylaxis.

  • 2

    A single intramuscular dose of rAAV-P2C5-Fc resulted in sustained antibody levels for over 1,120 days in common marmosets.

  • 3

    Complete protection against lethal SARS-CoV-2 variants was observed in mice up to 460 days post-administration.

  • 4

    Biodistribution studies indicated rAAV localization primarily at the injection site and regional lymph nodes with minimal off-target spread.

  • 5

    Moderate anti-AAV capsid antibody responses were detected, while anti-drug antibodies against P2C5-Fc remained undetectable.

Original Source(s)

Long-term protective potency of AAV vector-based SARS-CoV-2 prophylaxis in mice and non-human primates

  • by Ekaterina I. Ryabova, Artem A. Derkaev, Ilias B. Esmagambetov, Mikhail A. Dovgiy, Ilya V. Gordeychuk, Inna V. Shuliakova, Rosa M. Hossain, Anton A. Blinov, Anna A. Iliukhina, Daria M. Grousova, Ilya D. Zorkov, Daria V. Avdoshina, Stanislav A. Gulyaev, Vasiliy D. Apolokhov, Tatiana V. Gulyaeva, Irina A. Favorskaya, Dmitry V. Shcheblyakov, Alexander L. Gintsburg, Denis Y. Logunov

  • June 4, 2026

Related Content

Sustaining herd immunity against measles: Insights from a serological cohort study in an outbreak-free population

FDA Monthly Preview: Key June Decisions to Watch

Several FDA decisions across multiple specialties are expected this month.

Long COVID Persistence and Surveillance Gaps Across 58 US Hospitals